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http://dx.doi.org/10.1016/j.ccr.2013.04.012SUMMARYThe human epidermal growth factor receptor (HER) family of tyrosine kinases is deregulated in multiple
cancers either through amplification, overexpression, or mutation. ERBB3/HER3, the only member with an
impaired kinase domain, although amplified or overexpressed in some cancers, has not been reported to
carry oncogenic mutations. Here, we report the identification of ERBB3 somatic mutations in11% of colon
and gastric cancers. We found that the ERBB3 mutants transformed colonic and breast epithelial cells in a
ligand-independent manner. However, the mutant ERBB3 oncogenic activity was dependent on kinase-
active ERBB2. Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively
blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo.INTRODUCTION
The HER family of receptor tyrosine kinases (RTK), also known
as ERBB receptors, consists of four members—EGFR/ERBB1/
HER1, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4 (Base-
lga and Swain, 2009; Hynes and Lane, 2005). The ERBB family
members contain an extracellular domain (ECD), a single-span
transmembrane region, an intracellular tyrosine kinase domain,
and a C-terminal signaling tail (Burgess et al., 2003; Ferguson,
2008). The ECD is a four domain structure consisting of two L
domains (I and III) and two cysteine-rich domains (II and IV)
(Burgess et al., 2003; Ferguson, 2008). The ERBB receptorsSignificance
ERBB3, a kinase-impaired HER receptor tyrosine kinase family
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proteins are effective in blocking ERBB3 mutant-mediated onare activated by multiple ligands that include epidermal growth
factor (EGF), transforming growth factor-a (TGF-a), and neure-
gulins (Yarden and Sliwkowski, 2001). Activation of the receptor
involves a single ligand molecule binding simultaneously to
domains I and III, leading to heterodimerization or homodimeri-
zation through a dimerization arm in domain II (Burgess et al.,
2003; Cho and Leahy, 2002; Dawson et al., 2005; Lemmon and
Schlessinger, 2010; Ogiso et al., 2002). In the absence of ligand,
the domain II dimerization arm is tucked away via an intramolec-
ular interaction with domain IV, leading to a ‘‘tethered,’’ auto-
inhibited configuration (Burgess et al., 2003; Cho and Leahy,
2002; Ferguson et al., 2003; Lemmon and Schlessinger, 2010).member, heterodimerizes with ERBB2 upon ligand binding
RBB2-mediated oncogenic signaling. Whereas amplification
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ERBB3 Oncogenic MutationsAlthough the four ERBB receptors share a similar domain
organization, functional and structural studies have shown that
the ERBB2 does not bind any of the known ERBB family ligands
and is constitutively in an ‘‘untethered’’ (open) conformation suit-
able for dimerization (Garrett et al., 2003). In contrast, ERBB3,
although capable of ligand binding, heterodimerzation, and
signaling, has an impaired kinase domain (Baselga and Swain,
2009; Jura et al., 2009; Shi et al., 2010). Although, ERBB2 and
ERBB3 are functionally incomplete on their own, their hetero-
dimers are potent activators of cellular signaling (Holbro et al.,
2003; Pinkas-Kramarski et al., 1996; Tzahar et al., 1996).
Whereas the ERBB receptors are critical regulators of normal
growth and development, their deregulation has also been impli-
cated in the development and progression of cancers (Baselga
and Swain, 2009; Hynes and MacDonald, 2009; Sithanandam
and Anderson, 2008). In particular, gene amplification leading
to receptor overexpression and activating somatic mutations
are known to occur in ERBB2 and EGFR in various cancers
(Hynes and MacDonald, 2009; Sithanandam and Anderson,
2008; Wang et al., 2006; Yamauchi and Gotoh, 2009). This has
led to the development of multiple small molecule and anti-
body-based therapeutics that target EGFR and ERBB2 (Alvarez
et al., 2010; Baselga and Swain, 2009). Although the precise
role of ERBB4 in oncogenesis is not well established (Koutras
et al., 2010), transforming somatic mutations in ERBB4 have
been reported in melanoma (Prickett et al., 2009). Recently,
ERBB3 has emerged as a potential cancer therapeutic target,
given that it plays an important role in ERBB2 signaling and
acquired resistance to existing therapeutics (Amin et al., 2010;
Baselga and Swain, 2009). While ERBB3 amplification and/or
overexpression is known in some cancers, only sporadic occur-
renceofERBB3somaticmutationshasbeen reported (Dinget al.,
2008; Greenman et al., 2007; Jeong et al., 2006; Kan et al., 2010;
Stransky et al., 2011; TCGA, 2008, 2011). Furthermore, the func-
tional relevance of these mutations has not been studied. Given
the importance of ERBB3 in human cancers, we systematically
surveyed human cancers and identified recurrent somatic muta-
tions and show that these mutations are transforming. Further,
we evaluated targeted therapeutics in ERBB3 mutant-driven
animal models of cancer and show that a majority of them are
effective in blocking ERBB3 mutant-driven oncogenesis.
RESULTS
Identification of ERBB3 Mutations
In performing whole exome sequencing of 70 primary colon
tumors along with their matched normal samples, we identified
somatic mutations in ERBB3 (Seshagiri et al., 2012). To further
understand the prevalence of ERBB3 mutation in human solid
tumors, we sequenced all the coding exons of ERBB3 in a total
of 507 human primary tumor samples consisting of 100 colo-
rectal (70 samples from the whole exome screen [Seshagiri
et al., 2012], and 30 additional colon samples), 92 gastric,
71 non-small-cell lung (NSCLC) adenocarcinoma (adeno), 67
NSCLC (squamous), 45 renal carcinoma, 37 melanoma, 32
ovarian, 16 lung large cell, 15 esophageal, 12 small-cell lung can-
cer, 11 hepatocellular (HCC), and 9 other cancers (4 lung cancer
[other], 2 cecum, 1 lung [neuroendocrine], 1 pancreatic and 1
rectal cancer) (Table S1 available online). We found protein-604 Cancer Cell 23, 603–617, May 13, 2013 ª2013 Elsevier Inc.altering ERBB3 mutations in 12% of gastric (11/92), 11% of
colon (11/100), 1% of NSCLC (adeno; 1/71), and 1% of NSCLC
(squamous; 1/67) cancers (Table S1; Figure 1A). Although previ-
ous studies reported sporadic protein-altering ERBB3mutations
in NSCLC (squamous; 0.5% [3/188]; TCGA, 2008), glioblastoma
(1% [1/91]; TCGA, 2008), hormone-positive breast cancer (4%
[6/144]; Kan et al., 2010; Stephens et al., 2012), colon (1%
[1/100]; Jeong et al., 2006), ovarian (1% [3/339]; Greenman
et al., 2007; TCGA, 2011), gastric (10% [2/22]; Wang et al.,
2011), and head and neck cancer (1% [1/74]; Stransky et al.,
2011), none have evaluated their functional relevance in cancer
(Figure 1A; Tables S2 and S3). Additionally, recent large-scale
genomics studies reported ERBB3 mutations in colon (7%
[14/212]; TCGA, 2012a) and breast (2% [8/484]; TCGA, 2012b)
cancers. We confirmed all the mutations reported in this study
to be somatic by testing for their presence in the original tumor
DNA and absence in the matched adjacent normal tissue
through additional sequencing and/or mass spectrometric anal-
ysis. Besides the nonsynonymous mutations, we also found
three synonymous (nonprotein altering) mutations, one each in
colon, gastric, and ovarian cancers.
A majority of the mutations identified in the human tumors
clustered mainly in the ECD region, although some mapped to
the kinase domain and the intracellular tail of ERBB3. Interest-
ingly, among the ECD mutants were seven positions, V104,
A232, P262 G284, D297, G325, and T355, that contained recur-
rent substitutions across multiple samples, indicating that these
are mutational hot spots. Interestingly, the codon 104 mutation
was themost frequent andwas observed acrossmultiple studies
(Stephens et al., 2012; TCGA, 2012a, 2012b), indicating that it is
functionally relevant. Furthermore, a majority of the recurrent
missense substitutions at each of the hot spot positions resulted
in the same amino acid change, indicating a potential driver role
for these mutations. In addition to the ECD hot spots, our muta-
tion data meta-analysis identified two recurringmutations, S846I
and E928G, in the kinase domain (Jeong et al., 2006; TCGA,
2012a; Wang et al., 2011).
It is interesting to note that a majority of the mutated residues
identified were conserved across ERBB3 orthologs (Figure S1A),
indicating that these mutations likely have a functional effect.
To further understand themutations, wemapped them to pub-
lished ERBB3 ECD (Cho and Leahy, 2002) and kinase domain
(Jura et al., 2009; Shi et al., 2010) crystal structures (Figures
1B–1D; Figure S1B). Interestingly, the hot spot mutations at
V104, A232, and G284 cluster in the domain’s I/II interface.
The clustering of these three sites at the interface between
domains I and II suggests that theymay act via a commonmech-
anism. Domain II comprises several cystine-rich modules
arranged like vertebrae. Small changes in the relationship among
these semi-independent features have been assigned functional
importance among family members (Alvarado et al., 2009).
Perhaps the V104/A232/G284 mutations shift one or more of
these modules and cause an altered phenotype. The mutation
at P262 is at the base of domain II, close to Q271 involved in
the domain II/IV interaction required for the tethered, closed
conformation. D297 is adjacent to the long arm of domain II
and plays a role in heterodimerization under the influence of
bound ligand. The large conformational difference seen in family
members with and without ligand requires a hinge action at the
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Figure 1. ERBB3 Somatic Mutations
(A) ERBB3 nonsynonymous somatic mutations
(inverted triangles; red triangles depict hot spots;
for mutation details see Tables S3 and S4)
depicted over ERBB3 protein domains. The histo-
gram on the top represents a count of mutations at
each position observed in samples across studies
(Tables S3 and S4; red bars indicate hot spot
mutations and blue bars represent additional non-
hot spot mutants tested for activity).
(B and C) Hot spot somatic ECD mutations map-
ped onto a crystal structure of ‘‘tethered’’ ERBB3
ECD (Protein Data Bank [PDB]: 1M6B) (B), or onto a
model of ‘‘untethered’’ ERBB3/ERBB2 ECD het-
erodimer based on EGFR ECD dimer (PDB 1IVO)
(C), using ERBB3 (PDB 1M6B) and ERBB2 (PDB
1N8Z). The ERBB3 ligand shown in (C) as a gray
surface is based on EGF (PDB 1IVO).
(D) ERBB3 kinase domain somatic mutations
mapped on to a structure of the ERBB3 kinase
domain (PDB: 3LMG).
See also Figures S1 and Tables S1–S4.
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ERBB3 Oncogenic Mutationsborder between domains II and III, where G325 is found. Simi-
larly, T355 is also at the domain II/III border where large confor-
mational transitions are likely to occur. Kinase domain mutations
at residues 809 and 846 are homologous to positions proximal to
the path taken by the C-terminal tail in the EGFR kinase struc-
ture, a segment that has been assigned a role in endocytosis.
Residues at or near E928 are part of the protein/protein interface
observed in the asymmetric kinase dimer seen among X-ray
structures of ERBB family kinase domains. Most, but not all, of
the mutations described here are located at or near sites of func-
tional significance that affect ligand binding, heterodimer inter-
actions, large conformational transitions, or possible signaling
from subtle shifts among the modules in domain II. Details of
the exact nature of changes at these sites and their phenotypic
readout are beyond the scope of our current analysis. Sites of
other mutations observed in ERBB3 mapped onto its structure
are depicted in Figure S1B.
In an effort to understand the occurrence ofmutations in select
genes such as KRAS, HRAS, NRAS, BRAF, PIK3CA, andCancer Cell 23, 603–AKT1-3 in colon and gastric samples
with ERBB3 mutations, we sequenced
and analyzed an additional set of genes
in these samples. In 30% of instances,
we found that ERBB3 mutations were
independent of mutations in KRAS,
BRAF, or PIK3CA in colon cancers (Fig-
ure S1C; Table S4). In gastric cancers,
ERBB3 mutations were independent of
mutations in the receptor tyrosine kinase
pathway genes in 60% of the samples
(Figure S1C).
ERBB3 Mutants Promote
Anchorage-Independent Growth of
Colonic and Breast Epithelial Cells
Immortalized mouse colonic epithelial
(IMCE) cells can be transformed byexpression of oncogenic Ras (D’Abaco et al., 1996; Whitehead
et al., 1993). We used IMCE cells and tested ERBB3 mutants
for anchorage-independent growth, signaling, and in vivo tumor-
igenesis by stably expressing the ERBB3mutants either alone or
in combination with ERBB2. We found that the ERBB3-wild type
(WT) or the mutants when expressed on their own did not
promote anchorage-independent growth (Figures 2A and 2B).
However, a majority of the ERBB3 mutants, unlike the ERBB3-
WT, when co-expressed with ERBB2 promoted anchorage-
independent growth (Figures 2A and 2B). Consistent with the
anchorage-independent growth observed, a majority of the
IMCE cells expressing ERBB3 mutants along with ERBB2
showed elevated pERBB3 and/or pERBB2 and a concomitant
increase in pAKT and/or pERK (Figures 2C and 2D). Although
some of the ERBB3 mutants on their own showed elevated
pERBB3 (Figure 2C), it did not promote anchorage-independent
growth or downstream signaling. We tested if this was due to
an increase in the autophosphorylation activity of the mutants
in an in vitro kinase assay using purified recombinant ERBB3617, May 13, 2013 ª2013 Elsevier Inc. 605
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Figure 2. ERBB3 Mutants Support Transformation and In Vivo Tumor Growth of IMCE Colonic Epithelial Cells
(A–E) Representative images of anchorage-independent growth of IMCE colonic epithelial cells expressing either ERBB3-WT or mutants by themselves or
combinedwith ERBB2 (A), colony counts (mean ± SEM) (B), phosphor-signaling (C and D), and in vivo tumor growth (E); mean ± SEM (n = 10 animals for each arm)
compared to ERBB3-WT/ERBB2-expressing IMCE cells. EV, empty vector.
(F) Expression of ERBB2 and ERBB3 in ERBB3-mutant colon and gastric tumors as assessed by RNA-seq is expressed as reads per kilobase of exon model per
million mapped reads (RPKM). The dashed red, orange, and green lines mark the average upper bound value below which lies the expression of 90%, 75%, and
50%, respectively, of the protein coding genes expressed in these samples.
See also Figure S2.
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ERBB3 Oncogenic Mutationsproteins. As reported recently (Shi et al., 2010), we found that the
wild-type ERBB3 showed kinase activity (Figure S2A). However,
under the same in vitro assay conditions, we did not detect an
increase in the activity for the ERBB3 kinase mutants relative
to the ERBB3-WT kinase protein (Figure S2A). It is likely that
the observed increased pERBB3 level in cells expressing
ERBB3 mutants alone is due to interactions with other endoge-
nous ERBB family members in IMCE cells. To further confirm606 Cancer Cell 23, 603–617, May 13, 2013 ª2013 Elsevier Inc.the oncogenic activity of the ERBB3 mutants, we tested several
hot spot ECD mutant expressing cells for their ability to promote
tumor growth in vivo. Consistent with their ability to support
anchorage-independent growth and signaling, IMCE cells
co-expressing ERBB3 V104M, P262H, or G284R, along with
ERBB2 showed an increase in tumor growth (Figure 2E)
compared to ERBB3-WT or ERBB2 alone or ERBB3-WT and
ERBB2 combined. Consistent with the requirement for ERBB2
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Figure 3. ERBB3 Mutants Promote
Anchorage-Independent Growth, Prolifera-
tion, and Acinar Disruption
(A) Representative images depicting colonies
formed by MCF10A cells expressing ERBB3
mutants either alone or combined with ERBB2.
(B) Quantitation of the colonies from the assay
depicted in (A) is shown for ERBB3 mutants
coexpressed with ERBB2.
(C–F) EGF-independent proliferation (C), down-
stream signaling assessed by western blot (D),
acinar architecture (E), and Ki67 staining (F) of
MCF10A cells stably expressing ERBB3 mutants
together with ERBB2 compared to those ex-
pressing ERBB3-WT/ERBB2. Scale bars = 100 mm
in (E) and 50 mm in (F). Data in (B and C) represent
mean ± SEM of the three independent experi-
ments. Studies involving MCF10A were performed
in the absence of serum, EGF, and NRG1. EV,
empty vector.
See also Figure S3.
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ERBB3 Oncogenic Mutationsin ERBB3 mutant signaling, we confirmed the expression of the
ERBB3 mutants and the expression of ERBB2 (Figure S2) using
RNA-seq data (Seshagiri et al., 2012) in both colon and gastric
tumors. Furthermore, we found that the ERBB3 mutant human
primary tumor samples expressed both ERBB2 and ERBB3 at
high levels (Figures 2F and S2B–S2D). The expression of
ERBB2 and ERBB3 is significantly higher (p values of 4.102 3
105 and 2.05 3 106 for ERBB2 and ERBB3, respectively)
compared to the 75th percentile expression of all the protein cod-
ing genes expressed in the tumor samples (Figures 2F, S2C,
and S2D). Also, we found that the expression of ERBB2 and
ERBB3 was significantly high (p values of 1.143 3 103 and
1.096 3 105 to 4.102 3 105 for ERBB2 and ERBB3, respec-
tively) in the recent TCGA colon tumor data set (TCGA, 2012a;
Figure S2E). In addition, we found both ERBB3 and ERBB2 to
be expressed in CW-2 and DV-90, two recently identified
ERBB3 mutant cancer cell lines (Garnett et al., 2012), at a similarCancer Cell 23, 603–or higher level compared to ERBB3-
mutated tumors (Figure S2F). Further-
more, we confirmed that levels of
ectopically expressed ERBB3 and
ERBB2 at the protein level in IMCE cells
were comparable or lower than the levels
(Figure S2G) observed in ERBB3 mutant
cell lines, CW-2 and DV-90, further sup-
porting the relevance of ERBB3 mutants
in oncogenic signaling.
We further tested ERBB3 mutants for
their oncogenic activity using MCF10A
breast epithelial cells, given that ERBB3
mutations were also found in breast
tumors. The MCF10A cells require EGF
for proliferation (Petersen et al., 1992;
Soule et al., 1990) and can be rendered
EGF-independent upon expression of
oncogenes (Debnath et al., 2003; Mu-
thuswamy et al., 2001). Also, MCF10A
has been used to assess the oncogenicpotential of ERBB family members (Muthuswamy et al., 2001;
Wang et al., 2006). To further confirm the transforming activity
of the ERBB3mutants, we tested a subset of the ERBB3mutants
for their ability to promote EGF-independent growth, acinar for-
mation, signaling, anchorage-independent growth, and migra-
tion by stably expressing them alone or in combination with
ERBB2 in MCF10A cells (Figures 3A–3F and S3). We found
that when the ERBB3 mutants were expressed alone in
MCF10A and in the absence of exogenous ERBB3 ligand
NRG1 and EGF, there was no colony formation (Figure 3A). How-
ever, expression of ERBB3 mutants in combination with ERBB2
showed a significant increase in colony formation compared to
ERBB3-WT/ERBB2 cells (Figures 3A and 3B). Similarly, while
expression of ERBB3 mutant alone showed only a modest
ligand-independent proliferation, in the presence of ERBB2
they showed a significant increase in proliferation compared to
ERBB3-WT/ERBB2-expressing cells (Figure 3C). Additionally,617, May 13, 2013 ª2013 Elsevier Inc. 607
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Cancer Cell
ERBB3 Oncogenic Mutationswe observe elevated pERBB3, pAKT, and pERK in ERBB
mutant-expressing cells when compared to ERBB3-WT (Fig-
ure 3D). The increase in signaling in MCF10A cells expressing
ERBB3 alone is modest when compared to cells expressing
both ERBB3 and ERBB2 and is likely due to endogenous
EGFR present in the MCF10A cells (Figure 3D). In addition, the
ERBB3 mutants in combination with ERBB2 led to increased
level of pERBB3, pERBB2, pAKT, or pERK (Figure 3D).
MCF10A cells form acinar-cell spheroids when cultured on
reconstituted three-dimensional (3D) basement membrane gel
cultures in the presence of EGF (Muthuswamy et al., 2001;
Muthuswamy, 2011). However, expression of some oncogenes
can render them EGF-independent and also result in complex
multiacinar structures (Brummer et al., 2006; Bundy et al.,
2005; Debnath et al., 2003). In 3D culture studies lacking serum,
EGF, and NRG1, ectopic expression of ERBB3 mutants in com-
bination with ERBB2 in MCF10A cells promoted large acinar
structures compared to MCF10A cells that co-express ERBB3-
WT with ERBB2 (Figure 3E). Although ERBB2 overexpression
in MCF10A cells cultured in media containing serum and EGF
is known to disrupt acinar formation (Muthuswamy et al.,
2001), we did not observe this with ERBB2 because our studies
were done in the absence of serum, EGF, and NRG1. Staining for
Ki67, a marker for proliferation, in acini derived from ERBB3
mutant/ERBB2 co-expressing MCF10A cells showed increased
proliferation in all the mutants tested (Figure 3F). In addition, the
same MCF10A cells expressing a subset of the ERBB3 mutant
and ERBB2 also showed increased migration (Figures S3A and
S3B) compared to ERBB3-WT/ERBB2 cells. These results taken
together further confirm that the ERBB3mutants in the presence
of ERBB2 are capable of oncogenic signaling.
shRNA-Mediated ERBB3-Knockdown Impairs In Vivo
Tumor Growth
Having established the oncogenic activity of ERBB3 mutants in
IMCE cells, we sought to test the effect of knocking down
ERBB3 in tumor cell lines. A recent study reported ERBB3
E928G mutation in the CW-2 colon cell line, and ERBB3
V104M mutation in the DV-90 lung line (Garnett et al., 2012).
We used these lines to further test the relevance of ERBB3 in
tumor formation following targeted knockdown. In addition, we
used ERBB3-WT gastric linesOCUM-1 andMKN-74 as controls.
We generated stable CW-2, DV-90, OCUM-1, and MKN-74 cell
lines that expressed a previously published doxycycline (Dox)-
inducible shRNA that targets ERBB3 (Lee-Hoeflich et al.,
2008). As an additional control, we generated stable lines that
expressed a Dox-inducible luciferace (LUC) targeting shRNA.
We found that the induction of the ERBB3 or LUC targeting
shRNA in ERBB3-WT cell lines did not affect downstream
signaling (Figure 4A) or anchorage-independent growth (Figures
4B and 4C), although ERBB3 levels were decreased in these
lines (Figure 4A). However, in ERBB3 mutant lines, upon induc-Figure 4. shRNA-Mediated ERBB3 Knockdown Delays Tumor Growth
(A and D) Western blot showing levels of ERBB3 and pERK upon ERBB3 knockd
(B and E) Representative images showing anchorage-independent growth of cel
(C and F) Colony count from experiments depicted in (B) and (E). Data represent
(G–J) In vivo growth of ERBB3 mutant lines following induction of shRNA targeting
(n = 8 for each arm).tion of ERBB3 shRNA in contrast to LUC-shRNA, led to a
decrease in ERBB3 and a concomitant decrease in pERK (Fig-
ure 4D). Furthermore, we did not see a significant decrease in
pAKT (Figure 4D) following ERBB3 knockdown in CW-2 and
DV-90, and this likely is due to the mutations in KRAS and
PI3KCA found in these lines (Garnett et al., 2012). Additionally,
consistent with the loss of ERBB3 and pERK following Dox-
induction, both DV-90 and CW-2 showed reduced anchorage-
independent growth compared to LUC shRNA-expressing lines
or the uninduced lines (Figures 4E and 4F). We next tested
whether knockdown of ERBB3 in DV-90 and CW-2 cells might
affect their ability to form tumors in vivo. Upon Dox-mediated
induction of ERBB3 targeting shRNA, we found that both DV-
90 and CW-2 cells showed a significant decrease in tumor
growth compared to animals bearing DV-90 or CW-2 cells that
expressed LUC-shRNA or were not induced to express the
ERBB3 shRNA (Figures 4G–4J). These data are indicative of an
oncogenic role for ERBB3 in ERBB3 mutant lines.
ERBB3 Mutants Promote Interleukin-3-Independent
Cell Survival and Transformation
BaF3 is an interleukin (IL)-3 dependent pro-B cell line that has
been widely used to study oncogenic activity of genes and
development of drugs that target oncogenic drivers (Lee et al.,
2006; Warmuth et al., 2007). We used this system to test several
ERBB3 ECD mutants (V104M, A232V, P262H, G284R, and
T389K) that included five ECD-hot spot mutants and four
ERBB3 kinase domain mutants (V714M, Q809R, S846I, and
E928G) for their effects on interleukin-3 (IL-3)-independent cell
survival, signaling, and colony formation by stably expressing
the ERBB3 mutants either alone or in combination with
ERBB2. ERBB3 is kinase impaired and following ligand binding
it preferentially forms heterodimers with ERBB2 to promote
signaling (Holbro et al., 2003; Karunagaran et al., 1996; Lee-
Hoeflich et al., 2008; Sliwkowski et al., 1994). Consistent with
this, in the absence of exogenous ligand, ERBB3 WT and the
ERBB3 mutants on their own did not promote IL-3-independent
survival of BaF3 cells above background levels (Figure 5A). How-
ever, in the absence of exogenous ERBB3 ligand, the ERBB3
mutants, unlike ERBB3-WT, promoted (10- to 300-fold) IL-3-
independent BaF3 cell survival when co-expressed with
ERBB2 (Figure 5A), indicating that the ERBB3mutantsmay func-
tion in a ligand-independent fashion. The cell survival activity of
ERBB3 mutants was abrogated when they were co-expressed
with a kinase-dead (KD) ERBB2-K753M mutant, confirming
the requirement for a kinase-active ERBB2 (Figure 5A). We
further investigated ERBB3 mutants for their ability to promote
IL-3-independent colony formation. The ERBB3 mutants, on
their own, as observed in the survival assay, did not form col-
onies (Figure 5B). However, we found that a majority of the
ERBB3 mutants tested in combination with ERBB2 show
increased colony formation and growth when compared toin ERBB3 Mutant CW-2 and DV-90 Cells
own.
ls expressing a Dox-inducible shRNA targeting ERBB3 or LUC.
mean ± SEM.
ERBB3 (H and J) or luciferase (G and I). Data shown in (G)–(J) are mean ± SEM
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Figure 5. ERBB3 Mutants Transform and Promote IL-3-Independent Survival of BaF3 Cells
(A) IL-3-independent survival of BaF3 cells stably expressing ERBB3 mutants either alone or together with ERBB2 or ERBB2-KD.
(B) A representative image of colony formation by BaF3 cells stably expressing ERBB3 mutants either alone or in combination with either ERBB2 or ERBB2-KD.
(C) Bar graph (mean ± SEM) showing the number of colonies formed by BaF3 cells expressing the ERBB3 mutants along with ERBB2 depicted in (B).
(D–F) Western blot showing pERBB3, pERBB2, pAKT, and pERK status of BaF3 cells expressing ERBB3 mutants either alone (D) or in combination with ERBB2
(E) or ERBB2-KD (F).
(G) Effect of anti-NRG1, an NRG1 neutralizing antibody (Hegde et al., 2013; Figure S4A) on IL-3-independent survival of BaF3 cells promoted by ERBB3 mutants
co-expressed with ERBB2.
(legend continued on next page)
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ERBB3 Oncogenic MutationsERBB3-WT/ERBB2-expressing BaF3 cells (Figures 5B and 5C).
As observed in the proliferation assay, ERBB3 mutants in the
presence of ERBB2-K753M KD (ERBB2-KD) did not promote
colony formation (Figure 5B), confirming the requirement for
kinase-active ERBB2 in ERBB3 mutant-mediated oncogenic
signaling. Western blot analysis of the BaF3 cells showed that
the expression of ERBB3 mutants in combination with ERBB2
led to an increase in pERBB3, pERBB2, pAKT, and/or pERK
compared to ERBB3-WT (Figures 5D–5F). Consistent with the
lack of cell survival activity or colony formation, the ERBB3
mutants on their own or in combination with ERBB2-KD did
not show elevated pERBB2 and/or pAKT/pERK (Figures 5D
and 5F), although ERBB3 mutants on their own showed some
elevated pERBB3 levels that were likely due to low levels of
endogenous ERBBs expressed by BaF3 cells. However, this
moderate increase of pERBB3 in ERBB3 mutants alone was
not sufficient to increase pAKT and/or pERK and hence was un-
able to promote IL-3-independent cell survival or colony forma-
tion. In combination with ERBB2, the ERBB3 V714M kinase
domain mutant consistent with its weak signaling showed only
a modest cell survival activity and no colony formation (Figures
5A–5C). In contrast, Q809R, S846I, and E928G mutants in com-
bination with ERBB2 showed robust downstream signaling
compared to ERBB3-WT (Figures 5A–5C).
To further understand the mechanism by which the ERBB3
mutants promote oncogenic signaling, we tested the ligand
dependency of the ERBB3 mutants in our BaF3 system by treat-
ing these cells with an increasing dose of an ERBB3-ligand
neutralizing anti-NRG1 antibody (Hegde et al., 2013; Figure S4A).
We found that the addition of a NRG1 neutralizing antibody had
no effect on the ability of the ERBB3 mutants to promote IL-3-
independent survival (Figure 5G), indicating that this increase
in IL-3-independent survival of ERBB3 mutants is not due to
the presence of residual ligand NRG1 or the secretion of NRG1
by the BaF3 cells. Consistent with this, in the absence of ligand,
immunoprecipitation performed following cell surface receptor
crosslinking showed increased levels of ERBB3 mutant/ERBB2
heterodimers when compared to cells co-expressing ERBB3-
WT and ERBB2 (Figure S4B). This was further confirmed by
the elevated levels of cell surface heterodimers in BaF3 cells ex-
pressing ERBB3 mutant/ERBB2 cultured in the absence of IL-3
and NRG1 using a proximity ligation assay (So¨derberg et al.,
2006; Figures S4C–S4E). Although further studies will be needed
to understand the precisemechanism of oncogenic activation by
ERBB3 mutants, these observations suggest that the ERBB3
mutants, combined with ERBB2, are capable of signaling in a
NRG1-independent manner.
Having established that the ERBB3 mutants can signal
independent of ligand, we tested if their activity could be
augmented by ligand addition. We found that NRG1 was unable
to support survival of BaF3 cells expressing ERBB3-WT or the
mutants alone (Figure S4F). At the lower concentration range of
NRG1 tested, unlike ERBB3-WT, most of the ERBB3 mutants
except A232V in combination of ERBB2 did not increase IL-3-(H) Effect of increasing doses of exogenous NRG1 ligand on ERBB3 ECD mu
performed in the absence of IL-3 (A–H) and in the absence of NRG1 (A–F). Data sh
EV, empty vector.
See also Figure S4.independent survival. However, at the highest concentration
of exogenous NRG1 tested, a majority of the ERBB3 mutants,
when co-expressed with ERBB2, increased the IL-3-indepen-
dent survival of BaF3 cells (Figure 5H). Interestingly, the
A232V ERBB3 mutant, like ERBB3-WT, showed a NRG1
dose-dependent, IL-3-independent survival response (Fig-
ure 5H). In contrast, the more active ERBB3 mutants, G284R
and Q809R, did not show a significant increase in survival
following ligand addition when compared to untreated cells ex-
pressing these mutants. The minimal response to ligand addi-
tion by G284R ECD and Q809R kinase domain mutants sug-
gests a dominant role for the ligand-independent mode of
signaling by these mutants (Figure 5H). These results show
that while all the ERBB3 mutants are capable of ligand-inde-
pendent signaling, some of them are still capable of responding
to ligand stimulation.
ERBB3 Mutants Promote Oncogenesis In Vivo
We and others have shown that BaF3 cells, rendered IL-3-inde-
pendent by ectopic expression of oncogenes, promote leuke-
mia-like disease when implanted in mice and lead to reduced
overall survival (Horn et al., 2008; Jaiswal et al., 2009a). We
tested the ability of BaF3 cells expressing ERBB3-WT, two
ECD mutants (P262H or G284R), or the kinase domain
ERBB3 mutant (Q809R) together with ERBB2 for their ability
to promote leukemia-like disease. BaF3 cells transduced with
ERBB3-WT alone or ERBB2 together with empty vector were
used as controls. We found that mice transplanted with BaF3
cells expressing ERBB3 mutants together with ERBB2 showed
a median survival of 22–27 days (Figure 6A). In contrast, mice
receiving BaF3 cells expressing either ERBB3-WT alone or
ERBB2 with empty vector were all alive at the end of the
60-day study period. However, animals receiving BaF3 cells
co-expressing ERBB3-WT and ERBB2 developed leukemia-
like disease with a significantly longer latency (median survival,
39 days; Figure 6A). Although the ERBB3-WT/ERBB2 BaF3
cells in vitro did not show IL-3 independence, their activity in
the animal model is likely due to the presence of growth factors
and cytokines in vivo that can activate ERBB3-WT/ERBB2 di-
mers and in part due to ligand-independent signaling reported
for ERBB3-ERBB2 heterodimers (Junttila et al., 2009). To follow
disease progression, we conducted necropsies at 20 days on a
cohort of three mice per treatment. Bone marrow, spleen, and
liver samples from these animals were reviewed for pathologic
abnormalities. Because the BaF3 cells were tagged with GFP,
we examined isolated bone marrow and spleen for infiltrating
cells with fluorescence-activated cell sorting (FACS). Consis-
tent with the decreased survival, bone marrow and spleen
from mice transplanted with cells expressing ERBB3 mutants/
ERBB2 showed a significant increase in the proportion of infil-
trating GFP-positive cells compared with bone marrow and
spleen from mice receiving ERBB3-WT or ERBB2/empty vector
control cells (Figures 6B–6D). Furthermore, concordant with the
longer latency observed, a very low level of infiltratingtants/ERBB2-expressing BaF3 cells following IL-3 withdrawal. BaF3 studies
own in (A, G, and H) are mean ± SEM of at least three independent experiments.
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Figure 6. ERBB3 Mutants Promote Oncogenesis and Lead to Reduced Overall Survival
(A) Kaplan-Meier survival curves for cohorts of mice implanted with BaF3 cells expressing the indicated ERBB3mutant/ERBB2 combination compared to control
(EV) BaF3 cells (n = 10 for each arm; log-rank test p < 0.0001).
(B and C) Flow cytometric analysis of total bone marrow cells (B) and spleen cells (C) isolated frommice receiving GFP-tagged BaF3 cells expressing the various
ERBB3 mutants/ERBB2.
(D) Mean number (mean ± SEM) of GFP-positive cells in the bone marrow and spleen of mice (n = 3) from each study arm.
(E) Mean weights (mean ± SEM) of spleen and liver from the mice (n = 3) in the indicated study arms are depicted.
(F) Representative H&E-stained bonemarrow, spleen, and liver sections from the samemice analyzed in (B). The bonemarrow from EV animals consists of normal
hematopoietic cells. *Infiltrating tumor cells. R, red pulp; W, lymphoid follicles of white pulp. In the unmarked spleen section, there is a loss of red/white pulp
architecture due to disruption by infiltrating tumor cells. Scale bar = 100 mm. EV, empty vector.
See also Figure S5.
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ERBB3 Oncogenic MutationsGFP-positive cells were detected in the liver and spleen from
animals receiving ERBB3-WT/ERBB2 cells. Also, animals from
the ERBB3 mutant/ERBB2 arm showed increased spleen and
liver size and weight compared to empty vector control or
ERBB3-WT/ERBB2 (Figures 6E and S5), further confirming
the presence of infiltrating cells. Additionally, histologic evalua-
tion of hematoxylin and eosin (H&E) stained bone marrow,
spleen, and liver sections showed significant infiltration of
blasts in animals with cells expressing ERBB3 mutant/ERBB2
when compared to control at day 20 (Figure 6F). These results
demonstrate the in vivo oncogenic potential of the ERBB3
mutants.
Targeted Therapeutics Are Effective against ERBB3
Mutants
Multiple agents that target the ERBB receptors directly or their
downstream components are approved for treating various can-
cers (Alvarez et al., 2010; Baselga and Swain, 2009). Several
additional candidate drugs that target ERBB family members,
including ERBB3, and their downstream components are in
various stages of clinical testing and development (Alvarez
et al., 2010). We tested trastuzumab (an anti-ERBB2 antibody
that binds ERBB2 domain IV; Junttila et al., 2009), pertuzumab
(an anti-ERBB2 antibody that binds ERBB2 domain II and
prevents dimerization; Junttila et al., 2009), anti-ERBB3.1 (an
anti-ERBB3 antibody that binds domain II; Schaefer et al.,
2011), anti-ERBB3.2 (an anti-ERBB3 antibody that binds domain
III and blocks ligand binding; Wilson et al., 2011), MEHD7945A (a
dual ERBB3/EGFR antibody that binds to domain III of EGFR or
ERBB3 and blocks ligand binding; Schaefer et al., 2011), cetux-
imab (an anti-EGFR antibody that binds to domain III and blocks
ligand binding; Li et al., 2005), Lapatinib (a dual ERBB2/EGFR
small molecule inhibitor; Medina and Goodin, 2008), and GDC-
0941 (a PI3K inhibitor; Edgar et al., 2010) for their effects on
blocking cell survival and colony formation using the BaF3 sys-
tem (Figures 7 and S6A). We found that in both the survival
and colony formation assays, the small molecule inhibitor
Lapatinib was quite effective against all the mutants (Figures
7A and 7B), further confirming that the ERBB2 kinase activity
was needed for the oncogenic activity of the ERBB3 mutants.
However, while GDC-0941 was effective against all the mutants
tested, it was less effective against Q809R at the dose tested
(Figures 7A and 7B). We also tested the effect of PD0325901
(aMEK inhibitor; Thompson and Lyons, 2005) and a combination
of GDC-0941 and PD0325901 on proliferation of BaF3 cells
expressing the ERBB3 mutants. We found that combination of
GDC-0941 and PD-0325901 was quite effective in blocking all
the ERBB3 mutants, including the Q809R mutant (Figure S6B).
Among the antibodies tested in the colony formation assay,
trastuzumab, anti-ERBB3.2, and MEHD7945A were effective
against all the mutants tested (Figure 7B). However, pertuzumab
and anti-ERBB3.1, although very effective in blocking prolifera-
tion and colony formation induced by ERBB3 ECD mutants,
were only modestly effective against the Q809R kinase domain
ERBB3 mutant (Figures 7A and 7B). Consistent with this, in
BaF3 cells co-expressing mutant ERBB3 and ERBB2 in vitro,
these inhibitors, when efficacious, blocked or reduced pAKT
and/or pERK levels, and also the levels of ERBB3 and/or
pERBB3 (Figures 7C and S6C).We also tested the efficacy of trastuzumab, anti-ERBB3.1,
and anti-ERBB3.2 against G284R and Q809R ERBB3 mutants
using the BaF3 system in vivo (Figure 8). As observed in vitro,
trastuzumabwas very effective in blocking leukemia-like disease
in mice receiving BaF3 co-expressing G284R or Q809R ERBB3
mutant and ERBB2 (Figures 8A and 8B). Similarly, both anti-
ERBB3.1 and anti-ERBB3.2 blocked the development of
leukemia-like disease in mice receiving BaF3 co-expressing
G284R ERBB3 ECD mutant and ERBB2 (Figure 8A). However,
these anti-ERBB3 antibodies were only partially effective in
blocking disease development in mice receiving BaF3 cells
expressing Q809R ERBB3/ERBB2, although they significantly
improved survival compared to control antibody-treated animals
(Figure 8B). Consistent with the efficacy observed for the tar-
geted therapeutics, we found a significant decrease in infiltrating
BaF3 cells expressing the ERBB3 mutants in the spleen and
bone marrow (Figures 8C, 8D, and S7). Concomitant with the
observed reduced infiltration of BaF3 cells, the spleen and liver
weights (Figures 8E and 8F) were within the normal range ex-
pected for Balb/C nude mice (Figures 6E, 8E, and 8F). These
data indicate that multiple therapeutics, either in development
or approved for human use, can be effective against ERBB3
mutant-driven tumors.
DISCUSSION
In this study, we report the identification of ERBB3 somatic
mutations, including several hot spot mutations, which promote
oncogenic signaling in the presence of kinase-active ERBB2.
While some of the ECD mutants, V104M, A232V, P262H, and
T389K, were oncogenic in the absence of ERBB3 ligand
NRG1, they can be further stimulated by the addition of NRG1.
In contrast, the G284R (ECD) and Q809R (kinase domain)
mutants appear to be less sensitive to ligand-mediated activa-
tion, indicating a distinct mode of activation for these mutants.
We propose that the ECD mutations may shift the equilibrium
between tethered and untethered ERBB3ECD toward an unteth-
ered conformation relative to WT. Compared to the ECD
mutants, our functional data, and the location of these muta-
tions, suggest that the Q809R, S846I, and E928G ERBB3 kinase
domain mutant functions differently. Although the kinase domain
of ERBB3 is thought to be catalytically inactive, a recent study
reported a low level of kinase activity (Shi et al., 2010). In light
of this observation, one could surmise that the kinase domain
mutant, Q809R, S846I, and E928G, may have acquired an
elevated constitutive phosphotransferase activity and hence
became ligand independent. However, our inability to see any
increase in the phosphotransferase activity of ERBB3 Q809R
and E928G, under the assay conditions tested, suggests that
further experiments are required to support this possibility.
Another possibility is that the kinase domain mutation may alter
the conformation of ERBB3 so that it becomes more permissive
to form ERBB3/ERBB2 dimers in a ligand-independent fashion.
Determination of the precise mechanism of action of both the
ECD and kinase domain mutants requires further cellular,
biochemical, and structural studies.
Several targeted therapeutics that block signaling by ERBB
family members, including ERBB3, are in development or are
already used in the clinic to treat patients with cancer (BaselgaCancer Cell 23, 603–617, May 13, 2013 ª2013 Elsevier Inc. 613
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Figure 7. Efficacy of Anti-ERBB Antibodies and Small Molecule Inhibitors on Oncogenic Activity of ERBB3 Mutants
(A–C) Effect of targeted therapeutics on IL-3 independent proliferation (mean ± SEM) (A), representative images of colony formation assay (B), and signaling at
24 hr after treatment as assessed by western blot (C) of BaF3 cells stably expressing ERBB3 mutants together with ERBB2. The concentration of antibodies and
small molecule inhibitors used for treatment in (C) is same as that in (B).
See also Figure S6.
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Figure 8. Anti-ERBB3 Antibodies Are Effec-
tive against ERBB3 Mutants In Vivo
(A and B) Efficacy of trastuzumab (Tmab), anti-
ERBB3.1, and anti-ERBB3.2 antibodies in block-
ing leukemia-like disease induced by BaF3 cells
expressing ERBB3 G284R (A) or Q809Rmutant (B)
in combination with ERBB2 (n = 8 for each arm).
Anit-ragweed antibody was used as a control.
(C and D) Proportion of infiltrating BaF3 cells
expressing ERBB3G284R (C) or Q809R (D) mutant
in bone marrow and spleen following treatment
with the antibodies.
(E and F) Liver and spleen weight from animal
implanted with ERBB3 G284R (E) or Q809R (F)
mutant cells following treatment with the anti-
bodies as indicated. Data in (C)–(F) are mean ±
SEM (n = 3).
See also Figure S7.
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ERBB3 Oncogenic Mutationsand Swain, 2009). We found that multiple small molecule inhibi-
tors, anti-ERBB2, and anti-ERBB3 ECD antibodies were quite
effective in blocking oncogenic signaling by a majority of the
ERBB3 mutants. Interestingly, pertuzumab, anti-ERBB3.1, and
GDC-0941 were not as effective in blocking the kinase domain
mutant Q809R signaling, indicating a distinct mode of action
by this mutant. Previous studies have shown that while pertuzu-
mab is quite effective in blocking ligand-mediated ERBB3/
ERBB2 dimerization, trastuzumab is more effective in blocking
ligand-independent ERBB2/ERBB3 dimer formation (Junttila
et al., 2009). Consistent with this, the ligand nonresponsive
Q809R ERBB3 kinase domain mutant is much more responsive
to inhibition by trastuzumab compared to pertuzumab, suggest-
ing a potential role for a nonliganded heterodimeric complex in
Q809R ERBB3 signaling. Although the PI3K inhibitor GDC-
0941 is quite active against most of the ERBB3 mutants tested,Cancer Cell 23, 603–its reduced efficacy in blocking kinase
domainmutant suggests the engagement
of other downstream signaling molecules
besides the PI3K.
The presence of activating ERBB3
mutations increases the importance of
ERBB3 in cancer. However, further
studies are needed to fully elucidate the
mechanism of action of the ERBB3
mutants, their predictive and prognostic
values, and their contributions to ac-
quired resistance.
EXPERIMENTAL PROCEDURES
Samples and Mutation Detection
Appropriately consented primary human tumor
samples with institutional review board approval
were obtained from commercial sources (Table
S1). The human tissue samples used in the study
were de-identified (double-coded) prior to their
use and hence, the study using these samples is
not considered human subject research under
the US Department of Human and Health Services
regulations and related guidance (45 CFR Part 46).
Tumor content in all the tumors used was con-firmed to be >70% by pathology review. Tumor DNA was extracted using
the QIAGEN Tissue easy kit (QIAGEN, CA). All coding exons of ERBB3 in
tumor samples were amplified using primers in the Supplemental List. The
nested PCR reaction products were sequenced using ABI3730xl sequencer
(LifeTechnologies, CA). The sequencing data were analyzed for the presence
of variants not present in the dbSNP database using Mutation Surveyor
(Softgenetics, PA) and additional automated sequence alignment programs.
To confirm the somatic nature of the mutations, the putative variants iden-
tified were confirmed by DNA sequencing or mass spectrometry analysis
(Sequenom, CA) using the original tumor DNA followed by confirmation of its
absence in the adjacent matched normal DNA. Additional genes indicated in
Figure S1Cwere PCR amplified, sequenced, and analyzed in colon and gastric
tumors with ERBB3 mutations.
Animal Studies
All animal studies were conducted under protocols approved by Genentech’s
Institutional Animal Care and Use Committee guidelines. Further details on the
animal studies can be found in the Supplemental Experimental Procedures.617, May 13, 2013 ª2013 Elsevier Inc. 615
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Supplemental Information includes seven figures, four tables, Supplemental
Experimental Procedures, and one list and can be found with this article online
at http://dx.doi.org/10.1016/j.ccr.2013.04.012.
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